Eric Verdin

Arbeitsplatz: Japan, Osaka, CELL GRAND CLINIC
- Specialist at the clinic: Dr. Eric Verdin (President, Buck Institute for Research on Aging) is cited in the clinic’s NMN/NAD+ content for skepticism about intravenous NAD+ therapy.
- In a discussion with physician Peter Attia on The Drive (episode #359), he explained that NAD+ is too large to efficiently enter cells and is broken down into nicotinamide before it can be used.
- He recommends oral precursors such as NMN as a more practical approach to restoring NAD+ biology.
As a specialist at the clinic, Dr. Eric Verdin (President of the Buck Institute for Research on Aging) is referenced in the clinic’s NAD+ discussion for why intravenous NAD+ may not reach cells effectively. In a conversation with Peter Attia on The Drive (episode #359), he highlighted NAD+’s molecular size and described breakdown into nicotinamide before cellular use. The clinic’s longevity messaging therefore leans toward oral precursors like NMN as a more workable option.

Dienstleistungen des Arztes

Beratung durch einen Facharzt für Präventivmedizin

Wie läuft es für Sie mit uns?

1 von 3

Die Informationen über diesen Arzt sind vollständig und klar

Stimme nicht zu

Stimme stark zu

Qualifikationen

Dr. Eric Verdin, President of the Buck Institute for Research on Aging, is referenced by the clinic in its discussion of NAD+ and NMN. The clinic’s content focuses on a key mechanistic concern: whether intravenous NAD+ actually reaches the intracellular targets where it is needed. In a conversation with physician Peter Attia on The Drive (episode #359), Dr. Verdin explained that NAD+ is too large to efficiently enter cells and that much of it is broken down into nicotinamide before it can be used. Based on this reasoning, he recommends oral precursors such as NMN rather than relying on NAD+ infusions.

Education

Work experience

Buck Institute for Research on Aging — President (role stated in the clinic materials).

Clinical focus and techniques

Dr. Verdin’s contribution in the clinic materials is preventive and mechanistic: evaluating how NAD+ biology may be supported through precursors rather than direct NAD+ infusion.

NAD+ vs NMN cellular uptake considerations (molecular-size rationale described in the clinic’s NAD+ content).
Recommendation for oral NMN precursors over intravenous NAD+ (as described in the clinic’s cited discussion).

Professional societies and certifications

Academic output

Courses and advanced training

Awards and recognition

The clinic uses Dr. Verdin’s mechanistic critique to frame its longevity-related messaging around NAD+ restoration strategies. For patients, the practical takeaway presented in the clinic materials is that NMN is positioned as a more cell-uptake-friendly precursor than NAD+ for supporting NAD+ biology.